As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Arcturus Therapeutics Holdings Inc. The largest reported stake is ARK Investment Management LLC's, at 10.37%. 12 filings are on record since July 29, 2025 (Schedule 13G/A, May 7, 2026).
Sell to companies like Arcturus Therapeutics Holdings Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Sumitomo Mitsui Trust Group, Inc. · Sole voting: 0 · Shared voting: 1,689,107 · Sole dispositive: 0 · Shared dispositive: 1,689,107 · SCHEDULE 13G/A, 2026-10-29
- · Reporting person: Federated Hermes, Inc. · Sole voting: 1,678,069 · Shared voting: 0 · Sole dispositive: 1,678,069 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-07
- · Reporting person: ARK Investment Management LLC · Sole voting: 2,947,556 · Shared voting: 0 · Sole dispositive: 2,947,556 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-07
- · Reporting person: The Vanguard Group · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-03-26
- · Reporting person: Balyasny Asset Management L.P. · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-02-17
Arcturus Therapeutics Holdings Inc. has 12 Schedule 13D or 13G filings on record since 2025-07-29. 4 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| ARK Investment Management LLC | 10.37% | 2,947,556 | SCHEDULE 13G/A, 2026-05-07 | 2026-04-30 |
| Amova Asset Management Americas, Inc. | 7.2% | 1,947,835 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
| Sumitomo Mitsui Trust Group, Inc. | 5.9% | 1,689,107 | SCHEDULE 13G/A, 2026-10-29 | 2026-09-30 |
| Federated Hermes, Inc. | 5.9% | 1,678,069 | SCHEDULE 13G/A, 2026-10-07 | 2026-09-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
| Balyasny Asset Management L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Arcturus Therapeutics Holdings Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Arcturus Therapeutics Holdings Inc. and the records around it.
Arcturus Therapeutics Holdings Inc. elsewhere on the record
- Leadership changes May 2026
- Who owns it
Companies that share a holder
- Amova Asset Management Americas, Inc. also filed stake reports on 3 other companies: Ibotta, Inc. (Feb 2026), 10x Genomics, Inc. (Nov 2025)
- Sumitomo Mitsui Trust Group, Inc. also filed stake reports on 7 other companies: GCM Grosvenor Inc. (Apr 2026), Ibotta, Inc. (Feb 2026), 10x Genomics, Inc. (Oct 2025)
- Federated Hermes, Inc. also filed stake reports on 13 other companies: EyePoint (Nov 2026), Forte Biosciences, Inc. (Sep 2026), SCYNEXIS INC (Jul 2026)
Watch Arcturus Therapeutics Holdings Inc.
Get an email when Arcturus Therapeutics Holdings Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Arcturus Therapeutics Holdings Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Arcturus Therapeutics Holdings Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arcturus Therapeutics Holdings Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| ARK Investment Management LLC | 2,947,556 | 0 | 2,947,556 | 0 | SCHEDULE 13G/A, 2026-05-07 |
| Catherine D. Wood | 0 | 2,947,556 | 0 | 2,947,556 | SCHEDULE 13G/A, 2026-05-07 |
| Sumitomo Mitsui Trust Group, Inc. | 0 | 1,689,107 | 0 | 1,689,107 | SCHEDULE 13G/A, 2026-10-29 |
| Amova Asset Management Co., Ltd. | 0 | 1,689,107 | 0 | 1,689,107 | SCHEDULE 13G/A, 2026-10-29 |
| Federated Hermes, Inc. | 1,678,069 | 0 | 1,678,069 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| Voting Shares Irrevocable Trust | 1,678,069 | 0 | 1,678,069 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| Thomas R. Donahue | 0 | 1,678,069 | 0 | 1,678,069 | SCHEDULE 13G/A, 2026-10-07 |
| Ann C. Donahue | 0 | 1,678,069 | 0 | 1,678,069 | SCHEDULE 13G/A, 2026-10-07 |
| J. Christopher Donahue | 0 | 1,678,069 | 0 | 1,678,069 | SCHEDULE 13G/A, 2026-10-07 |
| The Vanguard Group | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-03-26 |
| Balyasny Asset Management L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-17 |
| Bam Gp LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-17 |
| Balyasny Asset Management Holdings LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-17 |
| Dames GP LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-17 |
| Dmitry Balyasny | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-17 |
The latest filing identifies Arcturus Therapeutics Holdings Inc. by CUSIP 03969T109 and gives its principal executive office as 10285 Science Center Drive, San Diego, CA 92121 (SCHEDULE 13G/A, 2026-10-29).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-29 | The Vanguard Group | 6.67% | SCHEDULE 13G/A |
| 2025-07-30 | ARK Investment Management LLC | 6.32% | SCHEDULE 13G/A |
| 2025-10-27 | Sumitomo Mitsui Trust Group, Inc. | 7.2% | SCHEDULE 13G/A |
| 2025-11-13 | Amova Asset Management Americas, Inc. | 7.2% | SCHEDULE 13G/A |
| 2025-11-14 | Balyasny Asset Management L.P. | 8.04% | SCHEDULE 13G |
| 2026-01-08 | Federated Hermes, Inc. | 11.63% | SCHEDULE 13G/A |
| 2026-02-03 | ARK Investment Management LLC | 9.19% | SCHEDULE 13G/A |
| 2026-02-17 | Balyasny Asset Management L.P. | 0% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-07 | ARK Investment Management LLC | 10.37% | SCHEDULE 13G/A |
| 2026-10-07 | Federated Hermes, Inc. | 5.9% | SCHEDULE 13G/A |
| 2026-10-29 | Sumitomo Mitsui Trust Group, Inc. | 5.9% | SCHEDULE 13G/A |
Questions about who owns Arcturus Therapeutics Holdings Inc.
Who owns Arcturus Therapeutics Holdings Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Arcturus Therapeutics Holdings Inc.: ARK Investment Management LLC (10.37%, Schedule 13G/A, filed 2026-05-07), Amova Asset Management Americas, Inc. (7.2%, Schedule 13G/A, filed 2025-11-13), Sumitomo Mitsui Trust Group, Inc. (5.9%, Schedule 13G/A, filed 2026-10-29) and Federated Hermes, Inc. (5.9%, Schedule 13G/A, filed 2026-10-07).
Who are the largest shareholders of Arcturus Therapeutics Holdings Inc.?
By the share each holder's latest filing reports, the largest holders of Arcturus Therapeutics Holdings Inc. on this page are ARK Investment Management LLC (10.37%), Amova Asset Management Americas, Inc. (7.2%) and Sumitomo Mitsui Trust Group, Inc. (5.9%).
When did ARK Investment Management LLC buy into Arcturus Therapeutics Holdings Inc.?
The filings give report dates, not purchase dates. The earliest filing from ARK Investment Management LLC on this page is the Schedule 13G/A, filed 2025-07-30, reporting 6.32%; its latest, Schedule 13G/A filed 2026-05-07, reports 10.37%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Arcturus Therapeutics Holdings Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 7, 2026 | Leadership change: Dennis Mulroy appointed, Chief Financial Officer, and 1 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Arcturus Therapeutics Holdings Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.